Uptake of non-vitamin K antagonist oral anti coagulants in patients with atrial fibrillation - a prospective cohort study
Matylda Zimny, Steffen Blum, Peter Ammann, Paul Erne, Giorgio Moschovitis, Marcello Di Valentino, Dipen Shah, Jürg Schläpfer, Cyrill Vogt, Alexandra Tabord, Michael Kühne, Christian Sticherling, Stefan Osswald & David Conen
After regulatory approval, the use of NOACs in Switzerland steadily increased to about 30% in 2015, whereas switches from VKAs to NOACs were infrequent. In parallel, the prescription of aspirin as monotherapy was more than halved, suggesting significant guideline-concordant improvements in oral anticoagulation use among patients with atrial fibrillation.
|citation||Zimny M, Blum S, Ammann P, Erne P, Moschovitis G, Di Valentino M, Shah D, Schläpfer J, Vogt C, Tabord A, Kühne M, Sticherling C, Osswald S, Conen D. Uptake of non-vitamin K antagonist oral anti coagulants in patients with atrial fibrillation - a prospective cohort study. Swiss Med Wkly 2017; 147:w14410.|
|type||journal paper/review (English)|
|date of publishing||21-03-2017|
|journal title||Swiss Med Wkly (147)|